Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey
Abstract We aimed to determine the use/prescription rates of biosimilars (BSs) among patients being treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This retrospective study included 647 patients with axial spondyloarthritis (axSpA) and rheumatoid arthr...
Saved in:
| Main Authors: | Hüseyin Kaplan, Gizem Cengiz, Hasan Kara, İsa Cüce, Mehmet Kirnap, Mustafa Çaliş |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-14816-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01) -
Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01) -
Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01) -
Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system
by: A. Yu Kulikov, et al.
Published: (2022-06-01) -
Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
by: V. I. Mazurov, et al.
Published: (2021-08-01)